ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Cefadroxil: Drug information

Cefadroxil: Drug information
(For additional information see "Cefadroxil: Patient drug information" and see "Cefadroxil: Pediatric drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
Brand Names: Canada
  • APO-Cefadroxil;
  • PRO-Cefadroxil-500 [DSC];
  • TEVA-Cefadroxil
Pharmacologic Category
  • Antibiotic, Cephalosporin (First Generation)
Dosing: Adult
Prosthetic joint infection, staphylococci, chronic oral antimicrobial suppression

Prosthetic joint infection, staphylococci (oxacillin-susceptible), chronic oral antimicrobial suppression (off-label use): Oral: 500 mg every 12 hours (Ref).

Skin and soft tissue infection

Skin and soft tissue infection:

Note: Not an appropriate agent if methicillin-resistant Staphylococcus aureus is suspected or confirmed (Ref).

Cellulitis (nonpurulent)/erysipelas, mild, treatment (alternative agent): Oral: 1 g once daily or 500 mg twice daily for 5 days; duration may be extended up to 14 days if not resolved/slow response (Ref).

Cellulitis, long-term suppression of recurrent infection: Note: For patients with recurrent presumptive staphylococcal cellulitis at the same anatomical site despite addressing predisposing factors (Ref).

Oral: 500 mg twice daily after completion of treatment (Ref).

Streptococcal pharyngitis, group A

Streptococcal pharyngitis, group A (alternative agent for mild, nonanaphylactic penicillin allergy):

Note: Cephalosporin selection depends on the type of hypersensitivity reaction to penicillin (Ref).

Oral: 1 g once daily for 10 days (Ref).

Urinary tract infection

Urinary tract infection (alternative agent):

Note: Use only when preferred agents cannot be used; limited evidence suggests inferior efficacy of oral beta-lactams (Ref).

Cystitis, acute uncomplicated or acute simple cystitis (infection limited to the bladder without signs/symptoms of upper tract, prostate, or systemic infection): Oral: 500 mg twice daily for 5 to 7 days (Ref).

Urinary tract infection, complicated (including pyelonephritis): Oral: 1 g twice daily for 10 to 14 days (Ref); for patients with symptomatic improvement within the first 48 to 72 hours of therapy, some experts recommend shorter courses of 7 to 10 days (Ref). Note: Oral beta-lactam therapy should generally follow appropriate parenteral therapy (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.

Altered kidney function:

Cefadroxil Maintenance Doses for Altered Kidney Functiona

CrCl

If the usual dose is 1 g every 24 hours or 500 mg every 12 hoursb

If the usual dose is 1 g twice dailyb,c

a Administer an initial dose of 1 g in all patients, then begin the recommended maintenance dose.

b Expert opinion.

c Leroy 1982.

≥40 mL/minute

No dosage adjustment necessary

No dosage adjustment necessary

20 to <40 mL/minute

500 mg every 24 hours

500 mg every 12 hours

<20 mL/minute

500 mg every 48 hours

500 mg every 24 hours

Hemodialysis, intermittent (thrice weekly): Dialyzable (63% removal following a 6- to 8-hour hemodialysis session) (Ref):

Oral:

If the usual recommended dose is 1 g every 24 hours or 500 mg every 12 hours: Administer 1 g once initially, followed by 500 mg 3 times weekly after hemodialysis sessions on hemodialysis days only (Ref).

If the usual recommended dose is 1 g every 12 hours: Administer 1 g once initially, followed by 1 g 3 times weekly after hemodialysis sessions on hemodialysis days only (Ref).

Peritoneal dialysis:

Oral:

If the usual recommended dose is 1 g every 24 hours or 500 mg every 12 hours: 1 g once initially, followed by 500 mg every 48 hours (Ref).

If the usual recommended dose is 1 g every 12 hours: 1 g once initially followed by 500 mg every 24 hours (Ref).

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer’s labeling.

Dosing: Older Adult

Refer to adult dosing.

Dosing: Pediatric

(For additional information see "Cefadroxil: Pediatric drug information")

General dosing: Infants, Children, and Adolescents: Oral: 30 mg/kg/day divided every 12 hours; maximum daily dose: 2,000 mg/day (Ref).

Impetigo

Impetigo: Children and Adolescents: Oral: 30 mg/kg/day once daily or in divided doses every 12 hours; maximum daily dose: 1,000 mg/day (Ref). Recommended duration is 7 days (Ref).

Osteoarticular infection, acute

Osteoarticular infection, acute (eg, septic [bacterial] arthritis, osteomyelitis): Step down therapy following parenteral treatment: Limited data available:

Infants, Children, and Adolescents: Oral: 75 to 150 mg/kg/day in divided doses every 6 to 8 hours; maximum dose: 4,000 mg/day (Ref). Minimum total duration is 2 to 3 weeks for septic arthritis and 3 to 4 weeks for osteomyelitis; however, duration should be individualized based on several factors, including causative pathogen, response to therapy, and normalization of inflammatory markers (Ref).

Skin and soft tissue infection

Skin and soft tissue infection: Children and Adolescents: Oral: 30 mg/kg/day in divided doses every 12 hours; maximum daily dose: 1,000 mg/day (Ref). Typical duration for uncomplicated infection is 5 days, but may be extended if clinical response is inadequate (Ref).

Streptococcus, group A; pharyngitis/tonsillitis

Streptococcus, group A; pharyngitis/tonsillitis (alternative agent for nonanaphylactic penicillin allergy):

Children and Adolescents: Oral: 30 mg/kg/day once daily or in divided doses every 12 hours for 10 days; maximum daily dose: 1,000 mg/day (Ref).

Urinary tract infection

Urinary tract infection: Children and Adolescents: Oral: 30 mg/kg/day divided every 12 hours; maximum daily dose: 2,000 mg/day (Ref). Duration of therapy should be individualized based on patient age, severity/extent of infection, and clinical response; typical duration is 7 to 14 days, though it may be as short as 3 to 5 days (eg, for uncomplicated cystitis in patients ≥2 years of age) (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

Note: Dosing based on a usual dose of 30 mg/kg/day in divided doses every 12 hours.

Altered kidney function:

Infants, Children, and Adolescents (Ref):

GFR ≥30 mL/minute/1.73 m2: Oral: No dosage adjustment necessary.

GFR 10 to 29 mL/minute/1.73 m2: Oral: 15 mg/kg/dose every 24 hours.

GFR <10 mL/minute/1.73 m2: Oral: 15 mg/kg/dose every 36 hours.

Hemodialysis, intermittent: Dialyzable (63% removal following a 6- to 8-hour hemodialysis session) (Ref):

Infants, Children, and Adolescents: Oral: 15 mg/kg/dose every 24 hours (Ref). Based on adult pharmacokinetic studies, three-times-weekly dosing after dialysis has also been recommended (Ref).

Peritoneal dialysis:

Infants, Children, and Adolescents: Oral: 15 mg/kg/dose every 36 hours (Ref).

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

1% to 10%: Gastrointestinal: Diarrhea

<1%: postmarketing, and/or case reports: Abdominal pain, agranulocytosis, anaphylaxis, angioedema, arthralgia, cholestasis, Clostridioides difficile-associated diarrhea, dyspepsia, erythema multiforme, erythematous rash, fever, genital candidiasis, hepatic failure, increased serum transaminases, maculopapular rash, nausea, neutropenia, pruritus, pseudomembranous colitis, serum sickness, Stevens-Johnson syndrome, thrombocytopenia, urticaria, vaginitis, vomiting

Contraindications

Hypersensitivity to cefadroxil, any component of the formulation, or other cephalosporins

Warnings/Precautions

Concerns related to adverse effects:

• Hypersensitivity reactions: Hypersensitivity reactions, including anaphylaxis, may occur. If an allergic reaction occurs, discontinue treatment and institute appropriate supportive measures.

• Penicillin allergy: Use with caution in patients with a history of penicillin allergy.

• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including C. difficile-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed >2 months postantibiotic treatment.

Disease-related concerns:

• Colitis: Use with caution in patients with a history of gastrointestinal disease, particularly colitis.

• Renal impairment: Use with caution in patients with renal impairment (CrCl <50 mL/minute/1.73 m2); dosage adjustment may be needed.

Dosage form specific issues:

• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggest that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer’s labeling.

• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated with hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP 1997; Zar 2007). See manufacturer’s labeling.

• Suspension: May contain sulfur dioxide (sulfite); hypersensitivity reactions, including anaphylaxis and/or asthmatic exacerbations, may occur (may be life threatening).

Warnings: Additional Pediatric Considerations

Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, >3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Capsule, Oral:

Generic: 500 mg

Suspension Reconstituted, Oral:

Generic: 250 mg/5 mL (100 mL); 500 mg/5 mL (75 mL, 100 mL)

Tablet, Oral:

Generic: 1 g

Generic Equivalent Available: US

Yes

Pricing: US

Capsules (Cefadroxil Oral)

500 mg (per each): $3.72

Suspension (reconstituted) (Cefadroxil Oral)

250 mg/5 mL (per mL): $0.61

500 mg/5 mL (per mL): $0.84

Tablets (Cefadroxil Oral)

1 g (per each): $7.78

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Capsule, Oral:

Generic: 500 mg

Administration: Adult

Oral: Administer around-the-clock to promote less variation in peak and trough serum levels. Administer without regards to meals; administration with food may diminish GI complaints.

Administration: Pediatric

Oral: May be administered without regard to food; administration with food may decrease GI complaints; shake suspension well before use.

Use: Labeled Indications

Skin and soft tissue infections: Treatment of skin and soft tissue infections caused by staphylococci and/or streptococci.

Streptococcal pharyngitis, group A: Treatment of pharyngitis and/or tonsillitis caused by Streptococcus pyogenes.

Urinary tract infection: Treatment of urinary tract infections caused by Escherichia coli, Proteus mirabilis, and Klebsiella species.

Use: Off-Label: Adult

Prosthetic joint infection with Staphylococci (oxacillin-susceptible)

Medication Safety Issues
Sound-alike/look-alike issues:

Duricef may be confused with Ultracet

Metabolism/Transport Effects

Substrate of OAT1/3

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Aminoglycosides: Cephalosporins may enhance the nephrotoxic effect of Aminoglycosides. Cephalosporins may decrease the serum concentration of Aminoglycosides. Risk C: Monitor therapy

Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii. Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy. Risk D: Consider therapy modification

BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). Risk X: Avoid combination

BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). Risk C: Monitor therapy

Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics. Risk X: Avoid combination

Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics. Risk X: Avoid combination

Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). Risk X: Avoid combination

Furosemide: May enhance the nephrotoxic effect of Cephalosporins. Risk C: Monitor therapy

Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). Risk C: Monitor therapy

Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. Risk C: Monitor therapy

Probenecid: May increase the serum concentration of Cephalosporins. Risk C: Monitor therapy

Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate. Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic. Risk D: Consider therapy modification

Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected. Management: Avoid use of live attenuated typhoid vaccine (Ty21a) in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose. Risk D: Consider therapy modification

Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists. Risk C: Monitor therapy

Pregnancy Considerations

Cefadroxil crosses the placenta (Takase 1980).

Based on available data, cephalosporin antibiotics are generally considered compatible for use during pregnancy; however, outcome information specific to maternal use of cefadroxil during pregnancy is limited compared to other cephalosporins (Ailes 2016; Bookstaver 2015; Crider 2009; Czeizel 2001; Lamont 2014; Muanda 2017a; Muanda 2017b; Nathorst-Böös 1995; Schedvins 1986).

Breastfeeding Considerations

Cefadroxil is present in breast milk.

The relative infant dose (RID) of cefadroxil is 2.6% when calculated using the highest breast milk concentration located and compared to a weight-adjusted maternal dose of 1 g/day.

In general, breastfeeding is considered acceptable when the RID of a medication is <10% (Anderson 2016; Ito 2000).

The RID of cefadroxil was calculated using a milk concentration of 2.4 mcg/mL, providing an estimated daily infant dose via breast milk of 360 mcg/kg/day. This milk concentration was obtained following maternal administration of cefadroxil 1 g to 6 mothers on the third postpartum day. The mean peak milk concentration was 1.83 mcg/mL (range: 1.2 to 2.4 mcg/mL) at 6 to 7 hours after the dose (Kafetzis 1981).

In general, antibiotics that are present in breast milk may cause non-dose-related modification of bowel flora. Monitor infants for GI disturbances (WHO 2002). The manufacturer recommends that caution be exercised when administering cefadroxil to breastfeeding women.

Monitoring Parameters

Monitor renal function. Observe for signs and symptoms of anaphylaxis during first dose.

Mechanism of Action

Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.

Pharmacokinetics (Adult Data Unless Noted)

Absorption: Rapid and well absorbed from GI tract.

Distribution: Vd: 0.31 L/kg.

Protein binding: 20%.

Half-life elimination:

Infants: 2.3 ± 0.5 hours (Windorfer 1982).

Children: Mean range: ~1.3 to 1.8 hours (Ginsburg 1978; Windorfer 1982).

Adults: 1 to 2 hours; 20 to 24 hours in renal failure.

Time to peak serum concentration: Within 70 to 90 minutes.

Excretion: Urine (>90% as unchanged drug within 24 hours).

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Anti-infective considerations:

Parameters associated with efficacy: Time dependent; associated with time free drug concentration (fT) > minimum inhibitory concentration (MIC). Goal: ≥40% to 50% (fT) > MIC (bacteriostatic), ≥60% to 70% (bactericidal) (Craig 1996; Craig 1998; Turnidge 1998).

Expected drug concentration in normal renal function:

Pediatric patients, Cmax (peak), single dose, oral:

Infants ≤10 months of age: 25 mg/kg: 24.8 ± 5.3 mg/L (Windorfer 1982).

Children:

15 mg/kg: ≤11 years of age: 11 to 13.7 mg/L (Ginsburg 1982).

25 mg/kg: ≤5 years of age: 21.2 ± 5 mg/L (Windorfer 1982).

Adults, Cmax (peak), oral:

Single dose:

500 mg: 17.9 ± 1 mg/L (La Rosa 1982).

1 g: 35.2 ± 0.6 mg/L (La Rosa 1982).

Steady state: 1 g every 8 hours: 35.5 ± 5.9 mg/L (Hampel 1982).

Postantibiotic effect : Generally <1 hour; varies by organism (Craig 1991; Craig 1998).

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Biodroxil | Cefadrox | Droxil | Duricef | Kefloxin | Roxil;
  • (AR) Argentina: Cefacar | Cefacilina | Cefadrox | Cefadroxilo Fabra | Cefamar | Cefasin | Cefatenk | Droxil | Kandicin | Klondroxil | Versatic;
  • (AT) Austria: Duracef;
  • (BD) Bangladesh: Adocef | Adocil | Adora | Arocef | Cedril | Cefador | Cefcare | Droxil | Ficef | Fodexil | Licef | Sefadol | Sefanid | Twicef;
  • (BE) Belgium: Cefadroxil merck-generics | Cefadroxil sandoz | Duracef | Moxacef;
  • (BF) Burkina Faso: Asmodrox | Biodroxyl | Oracefal;
  • (BG) Bulgaria: Biodroxil | Droxcef | Duracef | Valdocef;
  • (BR) Brazil: Cedroxil | Cefadroxila | Cefadroxon | Cefamox | Cefanaxil | Celocortin | Celoxin | Drocef | Drofaxil | Neo cefadril;
  • (CI) Côte d'Ivoire: Asmodrox | Bicef | Biodroxil | Kefdil | Oracefal | Oradroxyl | Saiforal | Sandrox | Sandrox ds | Serdroxil;
  • (CL) Chile: Adroxef | Biodroxil | Biogran | Cefadroxilo | Cefamox | Rafemox | Tridocylon;
  • (CN) China: Bai meng | Ding ke | Heng lin | Ji da wei de | Ji sai ou | Jin duo xin | Kang ke | Ke li xin | Li xin qi | Lv xin | Ou yi | Sai fu xi | Sai qiao xi | Sheng ou | Shu yi | Xi feng ling | Xian an | Xian feng jiu | Yuan xing mie di;
  • (CO) Colombia: Aurodrox | Biodroxil | Cefadroxilo | Duracef | Fadrox | Fazotec | Nafamed | Novadrox | Udrocef | Zolpra;
  • (CZ) Czech Republic: Biodroxil | Cedrox | Duracef | Valdocef;
  • (DE) Germany: Cefadroxil beta | Cefadroxil sandoz | Gruencef;
  • (DO) Dominican Republic: Bacteram | Biodroxil | Cedroxin | Cefa | Cefadrox | Cefadroxilo | Cefadroxilo Alfa | Cepha | Drocicef | Duracef | Garaxil | Lapricef | Lufradoxilo | Ossimixina;
  • (EC) Ecuador: Biodroxil | Cefadroxilo | Ceforal | Cetralon | Droxilon | Duracef;
  • (EE) Estonia: Duracef | Vedrox;
  • (EG) Egypt: Biodroxil | Cefaxoral | Cefex | Curisafe | Duricef | Ibidroxil | Ibidroxyl | Longicef;
  • (ES) Spain: Cefadroxilo | Duracef;
  • (FI) Finland: Cefadroxil generic | Cefadroxil Generics | Cefadroxil sandoz | Duracef;
  • (FR) France: Cefadroxil Biogaran | Cefadroxil g gam | Cefadroxil gnr | Cefadroxil ivax | Cefadroxil merck | Cefadroxil Ratiopharm | Cefadroxil teva | Oracefal;
  • (GB) United Kingdom: Cefadroxil sandoz;
  • (GR) Greece: Cefalom | Cyclomycine k | Kleotrat | Moxacef;
  • (HK) Hong Kong: Amben | Biodroxil | Droxion | Duracef | Duraxil | Qualidrox;
  • (HU) Hungary: Biodroxil;
  • (ID) Indonesia: Alxil | Ancefa | Bidicef | Biodroxil | Cefadroxil Soho | Cefat | Cefco | Dexacef | Dexadrox | Doxef | Droxal | Droxefa | Duricef | Ethicef | Grafacef | Kenfaxil | Lactacef | Lapicef | Librocef | Longcef | Lostacef | Opicef | Osadrox | Pyricef | Q cef | Qidrox | Renasistin | Sedrofen | Staforin | Tisacef | Valos | Vocefa | Widrox | Yaricef;
  • (IE) Ireland: Ultracef;
  • (IL) Israel: Duracef;
  • (IN) India: Acudrox | Adrocef | Anodox | Apdil | Aroxil | Bicef | Bid | Bidel | Bludrox | Bonaxyl | Cdr | Cedro | Cedrox | Cedroxil | Cedroxin | Cefabid | Cefad | Cefadrol | Cefadrox | Cefadur | Cefastar | Cefcare | Cefdronat | Cefind | Ceflad | Cefodril | Cefom | Ceforange | Cefoxid | Cefoxil | Cefril | Cefriz | Ceftic | Cefty | Cefzen | Cepdox | Cephbid | Cetron | Cexil | Codroxil | Cosdrox | Credroxil | Dax | Decacadroxil | Delcef | Doxycard | Droxibid | Droxibid p | Droxicef | Droxilite | Droxycad | Droxyceph | Droxyl | Duracef | Duroxyl | Eliminate | Endroxyl | Eudrox | Fedexil | Gigacef | Infadrox | Keecef | Kefdil | Kefexyl | Kefloxin | Kefzen | Kidrox | Lactocef | Lydroxil | Megadrox | Modcef | Neodrox | Nephelex | Ococef | Odoxil | Pd roxil | Pendrox | Puredrox | Qceph | Ridrox | Safedrox | Seadrox | Sunidrox | Swiceff | Vepan | Vindrox | Vistadrox | Waladrox | Zadro | Zedoxil | Zendrox | Zendroxyl | Zoxil;
  • (IT) Italy: Cefadril | Cephos | Droxicef | Oradroxil;
  • (JO) Jordan: Biodroxil | Cedrox | Cefadril | Cephos | Droxicef | Droxil | Duricef | Midroxil;
  • (JP) Japan: Cefadron | Dolucefan | Sedral banyu | Sedral torii | Sumacef bristol myers | Sumacef mochida | Sumacerud | Sumacerud choseido;
  • (KE) Kenya: Actidrox | Bidcef | Biodroxil | C drox | Cedril | Cefamed | Cefvac | Cexil | Curisafe | Dawadroxyl | Drox | Duraxyl | Flamicef | Ibidroxil | Mydrox | Odoxil | Vedrox;
  • (KR) Korea, Republic of: Aju cefadroxil | Anfadrox | Aprogen cefadroxil | Bidcef | Camex | Cefacel | Cefacell | Cefacil | Cefadil | Cefadro | Cefadrone | Cefadroxil yungjin | Cefaric | Cefaroxil | Cefodril | Cefoxil | Cefraxil | Cefroxil | Cellartcelaxin | Daewoong cefaroxil | Deroxil | Drocef | Drofa | Duricef | Evacef | Genuone cefadroxil | Glo cefadroxil | Hafroxil | Hanacef | Hanall cefadroxil | Hawon cefadroxil | Hwail cefadroxil | Il yang cefadroxil | Konicef | Kukje cefadroxil | Kwangdong cefadroxil | Medicefa | Neupad | Newgenpharm cefadroxil | Promerin | Safaraxil | Schnell cefadroxil | Unidroxil | Uricef | Urocef | Withucef;
  • (KW) Kuwait: Biodroxil | Droxil | Duricef;
  • (LB) Lebanon: Biodroxil | Cedroxyl | Cefadril | Curisafe | Duricef | Midroxil | Roxil;
  • (LT) Lithuania: Biodroxil | Duracef;
  • (LU) Luxembourg: Cefadroxil sandoz | Duracef | Moxacef;
  • (LV) Latvia: Biodroxil | Ceforal | Duracef;
  • (MA) Morocco: Biodroxil | Oracefal | Rodal;
  • (MX) Mexico: Cefadroxilo | Cefamox | Cepotec | Duracef | Kefloxin | Teroxina;
  • (MY) Malaysia: Androxyl | Anprodroxil | Cefradox | Droxyceph | Duricef | Kefloxin | Longcef | Sofidrox;
  • (NG) Nigeria: Longcef;
  • (PE) Peru: Adroxef | Biodroxil | Cafazit | Cedronar | Cefadroxilo | Cefotrix | Cefrabiotic | Droxilar | Duracef | Kefdyl;
  • (PH) Philippines: Cefadrox | Drolex | Droxil | Drozid | Lexipad | Wincocef;
  • (PK) Pakistan: A rox | Actacef | Acucef | Adrox | Ag-Drox | Aksocil | Aroxil | Astoxil | Baxef | Bd Rox | Bio oxil | Biodroxil | Bydoxil | C-doxil | Camex | Cedrox | Cedrox BD | Cefabact | Cefaroxin | Cefaxil | Cefroxil | Cepha | Ceroxil | Davox | Derfado | Drofin | Dromax | Droxim | Duraxic | Duricef | Efroxil | Envera | Evacef | Fedxil | Gefdrox | Grafadrox | Helicef | Hidrox | Indopol | Inforil | Jaycil | Joncef | Kanadrox | Kendrox | Lefdo | Maxdor | Maysa | Mecef | Neucef | Ofis | Oradrox | Oroxizaf | Osef | Oxibac | Ozix | Pedrox | Roxikef | Safdroxil | Say drox | Sephidrox | Sepnadox | Sidrox | Sionex | Sn rox | Sofilex | Solodrox | Sundox | Syroxil | Wedrox | Widrox | Xilporin | Z-drox | Zeboxil | Zylodrox;
  • (PL) Poland: Biodroxil | Duracef | Tadroxil;
  • (PR) Puerto Rico: Duricef;
  • (PT) Portugal: Biofaxil | Cefacile | Ceforal | Cefra-om;
  • (PY) Paraguay: Cefadroxilo 1 g cefen guayaki | Cefadroxilo dutriec | Cefrazol | Justum | Novosporal;
  • (QA) Qatar: Biodroxil | Cefadril | Curisafe | Droxil | Longicef | Midroxil | Roxil;
  • (RO) Romania: Cefadroxil terapia | Ceforan | Cexyl | Duracef;
  • (RU) Russian Federation: Duracef;
  • (SA) Saudi Arabia: Apo cefadroxil | Biodroxil | Cefadril | Cefadrox | Droxil | Midroxil | Ultracef;
  • (SE) Sweden: Cefadroxil merck nm | Cefadroxil mylan | Cefadroxil sandoz | Cefamox;
  • (SG) Singapore: Androxyl | Biodroxil | Dexacef | Duricef | Sofidrox;
  • (SI) Slovenia: Omnidrox | Valdiocef;
  • (SK) Slovakia: Biodroxil | Cedrox | Duracef;
  • (TH) Thailand: Cefadril | Duricef;
  • (TN) Tunisia: Cedrox | Oracefal | Oraxil | Saiforal;
  • (TR) Turkey: Cefradur | Duricef;
  • (TW) Taiwan: Cefaxil | Cendmycin | Cephadroxil | Cephos | Dolucefan | Duracef | Ibidroxyl | Infaxil | Likodin | Lonfadroxil | Sedral | Ucefa | Wincef;
  • (UA) Ukraine: Biodroxil | Cedrox | Cefadrox | Cefangin | Duracef;
  • (UG) Uganda: Drox;
  • (UY) Uruguay: Cefadroxilo | Cefamox | Curisafe;
  • (VE) Venezuela, Bolivarian Republic of: Aurodrox | Bidroxyl | Cedroxim | Cefadril | Cefadroxilo | Cefaval | Cefonax | Drocef | Droxifan | Grunicef | Kefloxin | Sanodril | Unidroxy;
  • (VN) Viet Nam: Droxistad | Fabadroxil | Fimadro | Hataroxil dht | Opedroxil | Pyfadrox;
  • (ZA) South Africa: Cefadrox | Cipadur | Dacef | Duracef;
  • (ZM) Zambia: Cedril | Cexil | Odoxil | Zoxil
  1. Afolabi TM, Goodlet KJ, Fairman KA. Association of antibiotic treatment duration with recurrence of uncomplicated urinary tract infection in pediatric patients. Ann Pharmacother. 2020;54(8):757-766. doi:10.1177/1060028019900650 [PubMed 31958969]
  2. Ailes EC, Gilboa SM, Gill SK, et al; The National Birth Defects Prevention Study. Association between antibiotic use among pregnant women with urinary tract infections in the first trimester and birth defects, National Birth Defects Prevention Study 1997 to 2011. Birth Defects Res A Clin Mol Teratol. 2016;106(11):940-949. doi:10.1002/bdra.23570 [PubMed 27891788]
  3. American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. Red Book: 2021-2024 Report of the Committee on Infectious Diseases. 32nd ed. American Academy of Pediatrics; 2021.
  4. American Dental Association Council on Scientific Affairs. Combating antibiotic resistance [published correction appears in: J Am Dent Assoc. 2004;135(6):727.]. J Am Dent Assoc. 2004;135(4):484-487. [PubMed 15127872]
  5. Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. J Pediatr. 2001;139(2):317-319. [PubMed 11487763]
  6. Anderson PO, Sauberan JB. Modeling drug passage into human milk. Clin Pharmacol Ther. 2016;100(1):42-52. doi:10.1002/cpt.377 [PubMed 27060684]
  7. Aronoff GR, Bennett WM, Berns JS, et al. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children. 5th ed. American College of Physicians; 2007.
  8. Balighian E, Burke M. Urinary tract infections in children. Pediatr Rev. 2018;39(1):3-12. doi:10.1542/pir.2017-0007 [PubMed 29292282]
  9. Ballantyne FN. Comparative efficacy of cefadroxil and cefaclor in the treatment of skin and soft-tissue infections. Clin Ther. 1985;7(4):487-491. [PubMed 4016827]
  10. Bookstaver PB, Bland CM, Griffin B, Stover KR, Eiland LS, McLaughlin M. A review of antibiotic use in pregnancy. Pharmacotherapy. 2015;35(11):1052-1062. doi:10.1002/phar.1649 [PubMed 26598097]
  11. Bucko AD, Hunt BJ, Kidd SL, Hom R. Randomized, double-blind, multicenter comparison of oral cefditoren 200 or 400 mg BID with either cefuroxime 250 mg BID or cefadroxil 500 mg BID for the treatment of uncomplicated skin and skin-structure infections. Clin Ther. 2002;24(7):1134-1147. doi:10.1016/s0149-2918(02)80024-8 [PubMed 12182257]
  12. Cefadroxil capsules [prescribing information]. East Windsor, NJ: Aurobindo Pharma USA Inc; May 2022.
  13. Cefadroxil capsules [prescribing information]. North Wales, PA: Teva Pharmaceuticals; June 2014.
  14. Cefadroxil capsules [product monograph]. Toronto, Ontario, Canada: Apotex Inc; February 2021.
  15. Cefadroxil suspension [prescribing information]. East Windsor, NJ: Aurobindo Pharma USA Inc; September 2021.
  16. Cefadroxil suspension [prescribing information]. Jacksonville, FL: Ranbaxy Pharmaceuticals Inc; August 2012.
  17. Cefadroxil tablets [prescribing information]. North Wales, PA: Teva Pharmaceuticals; June 2014.
  18. Cefadroxil tablets [prescribing information]. North Wales, PA: Teva Pharmaceuticals; July 2018.
  19. Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. MMWR Morb Mortal Wkly Rep. 1982;31(22):290-291. http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm [PubMed 6810084]
  20. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26(1):1-10; quiz 11-12. doi:10.1086/516284 [PubMed 9455502]
  21. Craig WA. The postantibiotic effect. CMNEEJ. 1991;13(16)121-128.
  22. Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J. 1996;15(3):255-259. doi:10.1097/00006454-199603000-00015 [PubMed 8852915]
  23. Crider KS, Cleves MA, Reefhuis J, Berry RJ, Hobbs CA, Hu DJ. Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study. Arch Pediatr Adolesc Med. 2009;163(11):978-985. doi:10.1001/archpediatrics.2009.188 [PubMed 19884587]
  24. Cronberg S, Banke S, Bruno AM, et al. Ampicillin plus mecillinam vs. cefotaxime/cefadroxil treatment of patients with severe pneumonia or pyelonephritis: a double-blind multicentre study evaluated by intention-to-treat analysis. Scand J Infect Dis. 1995;27(5):463-468. [PubMed 8588136]
  25. Cutler RE, Blair AD, Kelly MR. Cefadroxil kinetics in patients with renal insufficiency. Clin Pharmacol Ther. 1979;25(5, pt 1):514-521. [PubMed 436355]
  26. Czeizel AE, Rockenbauer M, Sørensen HT, Olsen J. Use of cephalosporins during pregnancy and in the presence of congenital abnormalities: a population-based, case-control study. Am J Obstet Gynecol. 2001;184(6):1289-1296. doi:10.1067/mob.2001.113905 [PubMed 11349204]
  27. DeRonde KJ, Girotto JE, Nicolau DP. Management of pediatric acute hematogenous osteomyelitis, part I: antimicrobial stewardship approach and review of therapies for methicillin-susceptible Staphylococcus aureus, Streptococcus pyogenes, and Kingella kingae. Pharmacotherapy. 2018;38(9):947-966. doi:10.1002/phar.2160 [PubMed 29920709]
  28. Donaldson N, Sanders J, Child J, Parker S. Acute hematogenous bacterial osteoarticular infections in children. Pediatr Rev. 2020;41(3):120-136. doi:10.1542/pir.2018-0201 [PubMed 32123023]
  29. Donowitz GR, Mandell GL. Drug therapy. Beta-lactam antibiotics (2). N Engl J Med. 1988;318(8):490-500. doi: 10.1056/NEJM198802253180806. [PubMed 3277054]
  30. Donowitz GR, Mandell GL. Beta-Lactam antibiotics (1). N Engl J Med. 1988;318(7):419-426. doi: 10.1056/NEJM198802183180706. [PubMed 3277053]
  31. Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.
  32. Fox MT, Amoah J, Hsu AJ, Herzke CA, Gerber JS, Tamma PD. Comparative effectiveness of antibiotic treatment duration in children with pyelonephritis. JAMA Netw Open. 2020;3(5):e203951. doi:10.1001/jamanetworkopen.2020.3951 [PubMed 32364593]
  33. Ginsburg CM. Comparative pharmacokinetics of cefadroxil, cefaclor, cephalexin and cephradine in infants and children. J Antimicrob Chemother. 1982;10(suppl B):27-31. doi:10.1093/jac/10.suppl_b.27 [PubMed 7142090]
  34. Ginsburg CM, McCracken GH Jr, Clahsen JC, Thomas ML. Clinical pharmacology of cefadroxil in infants and children. Antimicrob Agents Chemother. 1978;13(5):845-848. doi:10.1128/AAC.13.5.845 [PubMed 666305]
  35. Greenberg RN, Reilly PM, Luppen KL, Weinandt WJ, Ellington LL, Bollinger MR. Randomized study of single-dose, three-day, and seven-day treatment of cystitis in women. J Infect Dis. 1986;153(2):277-282. [PubMed 3484773]
  36. Gupta K. Acute complicated urinary tract infection (including pyelonephritis) in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed December 16, 2022b.
  37. Gupta K. Acute simple cystitis in adult males. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed January 6, 2023.
  38. Gupta K. Acute uncomplicated cystitis in females. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed December 16, 2022a.
  39. Gupta K, Hooton TM, Naber KG, et al; Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52(5):e103-120. doi:10.1093/cid/ciq257 [PubMed 21292654]
  40. Gustaferro CA, Steckelberg JM. Cephalosporin antimicrobial agents and related compounds. Mayo Clin Proc. 1991;66(10):1064-1073. [PubMed 1921490 ]
  41. Hampel B, Lode H, Wagner J, Koeppe P. Pharmacokinetics of cefadroxil and cefaclor during an eight-day dosage period. Antimicrob Agents Chemother. 1982;22(6):1061-1063. doi:10.1128/AAC.22.6.1061 [PubMed 7159069]
  42. Hooton TM, Winter C, Tiu F, Stamm WE. Randomized comparative trial and cost analysis of 3-day antimicrobial regimens for treatment of acute cystitis in women. JAMA. 1995;273(1):41-45. [PubMed 7654268]
  43. Humbert G, Leroy A, Fillastre JP, Godin M. Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency. Chemotherapy. 1979;25(4):189-195. doi:10.1159/000237839 [PubMed 456077]
  44. "Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. Pediatrics. 1997;99(2):268-278. [PubMed 9024461]
  45. Ito S. Drug therapy for breast-feeding women. NEJM. 2000;343(2):118-126. doi:10.1056/NEJM200007133430208 [PubMed 10891521]
  46. Kafetzis DA, Siafas CA, Georgakopoulos PA, Papadatos CJ. Passage of cephalosporins and amoxicillin into the breast milk. Acta Paediatr Scand. 1981;70(3):285-288. doi:10.1111/j.1651-2227.1981.tb16553.x [PubMed 7246123]
  47. La Rosa F, Ripa S, Prenna M, Ghezzi A, Pfeffer M. Pharmacokinetics of cefadroxil after oral administration in humans. Antimicrob Agents Chemother. 1982;21(2):320-322. doi:10.1128/AAC.21.2.320 [PubMed 7073267]
  48. Lamont HF, Blogg HJ, Lamont RF. Safety of antimicrobial treatment during pregnancy: a current review of resistance, immunomodulation and teratogenicity. Expert Opin Drug Saf. 2014;13(12):1569-1581. doi:10.1517/14740338.2014.939580 [PubMed 25189188]
  49. Lashkar MO, Nahata MC. Antimicrobial pharmacotherapy management of urinary tract infections in pediatric patients. J Pharm Technol. 2018;34(2): 62-81. doi:10.1177/8755122518755402 [PubMed 34860955]
  50. Leroy A, Humbert G, Godin M, Fillastre JP. Pharmacokinetics of cefadroxil in patients with impaired renal function. J Antimicrob Chemother. 1982;10(suppl B):39-46. doi:10.1093/jac/10.suppl_b.39 [PubMed 7142092]
  51. Lorrot M, Gillet Y, Gras Le Guen C, Launay E, Cohen R, Grimprel E. Antibiotic therapy of bone and joint infections in children: proposals of the French Pediatric Infectious Disease Group. Arch Pediatr. 2017;24(12S):S36-S41. doi:10.1016/S0929-693X(17)30517-1 [PubMed 29290233]
  52. Marshall WF, Blair JE. The cephalosporins. Mayo Clin Proc. 1999;74(2):187-195. doi:10.4065/74.2.187 [PubMed 10069359]
  53. Muanda FT, Sheehy O, Bérard A. Use of antibiotics during pregnancy and the risk of major congenital malformations: a population based cohort study. Br J Clin Pharmacol. 2017a;83(11):2557-2571. doi:10.1111/bcp.13364 [PubMed 28722171]
  54. Muanda FT, Sheehy O, Bérard A. Use of antibiotics during pregnancy and risk of spontaneous abortion. CMAJ. 2017b;189(17):E625-E633. doi:10.1503/cmaj.161020 [PubMed 28461374]
  55. Nathorst-Böös J, Philipson A, Hedman A, Arvisson A. Renal elimination of ceftazidime during pregnancy. Am J Obstet Gynecol. 1995;172(1 Pt 1):163-166. doi:10.1016/0002-9378(95)90107-8 [PubMed 7847529]
  56. Osmon DR, Berbari EF, Berendt AR, et al; Infectious Diseases Society of America. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2013;56(1):e1-e25. doi:10.1093/cid/cis803 [PubMed 23223583]
  57. Peltola H, Pääkkönen M, Kallio P, Kallio MJ; Osteomyelitis-Septic Arthritis Study Group. Short- versus long-term antimicrobial treatment for acute hematogenous osteomyelitis of childhood: prospective, randomized trial on 131 culture-positive cases. Pediatr Infect Dis J. 2010;29(12):1123-1128. doi:10.1097/INF.0b013e3181f55a89 [PubMed 20842069]
  58. Pichichero ME. Treatment and prevention of streptococcal pharyngitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed May 26, 2021.
  59. Refer to manufacturer's labeling.
  60. Saavedra-Lozano J, Falup-Pecurariu O, Faust SN, et al. Bone and joint infections. Pediatr Infect Dis J. 2017;36(8):788-799. doi:10.1097/INF.0000000000001635 [PubMed 28708801]
  61. Sandberg T, Englund G, Lincoln K, Nilsson LG. Randomised double-blind study of norfloxacin and cefadroxil in the treatment of acute pyelonephritis. Eur J Clin Microbiol Infect Dis. 1990;9(5):317-323. doi:10.1007/BF01973737 [PubMed 2197091]
  62. Schachner LA, Torrelo A, Grada A, et al. Treatment of impetigo in the pediatric population: consensus and future directions. J Drugs Dermatol. 2020;19(3):281-290. [PubMed 32550690]
  63. Schedvins K, Moberg PJ. Prevention of postoperative infection in cesarean section after rupture of the membranes. Int J Gynaecol Obstet. 1986;24(3):165-168. doi:10.1016/0020-7292(86)90093-7 [PubMed 2880755]
  64. Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. Pediatr Crit Care Med. 2009;10(2):256-259. [PubMed 19188870]
  65. Shulman ST, Bisno AL, Clegg HW, et al; Infectious Diseases Society of America. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America [published correction appears in Clin Infect Dis. 2014;58(10):1496]. Clin Infect Dis. 2012;55(10):e86-e102. doi: 10.1093/cid/cis629. [PubMed 22965026]
  66. Smith GH. Oral cephalosporins in perspective. DICP. 1990;24(1):45-51. [PubMed 2405586]
  67. Spelman D, Baddour LM. Acute cellulitis and erysipelas in adults: Treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed July 26, 2023.
  68. Stein R, Dogan HS, Hoebeke P, et al. Urinary tract infections in children: EAU/ESPU guidelines. Eur Urol. 2015;67(3):546-558. doi:10.1016/j.eururo.2014.11.007 [PubMed 25477258]
  69. Stevens DL, Bisno AL, Chambers HF, et al; Infectious Diseases Society of America (IDSA). Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10-e52. doi:10.1093/cid/ciu444 [PubMed 24973422]
  70. Takase Z, Shirafuji H, Uchida M. Experimental and clinical studies of cefadroxil in the treatment of infections in the field of obstetrics and gynecology. Chemotherapy (Tokyo). 1980;28(suppl 2):S424-S431.
  71. Turnidge JD. The pharmacodynamics of beta-lactams. Clin Infect Dis. 1998;27(1):10-22. doi:10.1086/514622 [PubMed 9675443]
  72. Wible K, Tregnaghi M, Bruss J, Fleishaker D, Naberhuis-Stehouwer S, Hilty M. Linezolid versus cefadroxil in the treatment of skin and skin structure infections in children. Pediatr Infect Dis J. 2003;22(4):315-323. doi:10.1097/01.inf.0000059403.21440.2c [PubMed 12690270]
  73. Wilson W, Taubert KA, Gewitz M, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee; American Heart Association Council on Cardiovascular Disease in the Young; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Cardiovascular Surgery and Anesthesia; Quality of Care and Outcomes Research Interdisciplinary Working Group. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group [published correction appears in: Circulation. 2007;116(15):e376-e377.]. Circulation. 2007;116(15):1736-1754. doi:10.1161/CIRCULATIONAHA.106.183095 [PubMed 17446442]
  74. Windorfer A, Bauer P. Pharmacokinetics and clinical studies with cefadroxil in paediatrics. J Antimicrob Chemother. 1982;10(suppl B):S85-S91. doi:10.1093/jac/10.suppl_b.85 [PubMed 7142099]
  75. Woods CR, Bradley JS, Chatterjee A, et al. Clinical practice guideline by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America (PIDS/IDSA): 2021 guideline on diagnosis and management of acute hematogenous osteomyelitis in pediatrics. J Pediatric Infect Dis Soc. 2021;10(8):801-844. doi:10.1093/jpids/piab027 [PubMed 34350458]
  76. World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. http://www.who.int/maternal_child_adolescent/documents/55732/en/
  77. Yahav D, Franceschini E, Koppel F, et al; Bacteremia Duration Study Group. Seven versus 14 days of antibiotic therapy for uncomplicated gram-negative bacteremia: a noninferiority randomized controlled trial. Clin Infect Dis. 2019;69(7):1091-1098. doi:10.1093/cid/ciy1054 [PubMed 30535100]
  78. Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. Semin Dial. 2007;20(3):217-219. doi:10.1111/j.1525-139X.2007.00280.x [PubMed 17555487]
Topic 9212 Version 326.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟